Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/24267
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Mistry, Anoop | - |
dc.contributor.author | Savic, Sinisa | - |
dc.contributor.author | VAN DER HILST, Jeroen | - |
dc.date.accessioned | 2017-08-18T11:54:14Z | - |
dc.date.available | 2017-08-18T11:54:14Z | - |
dc.date.issued | 2017 | - |
dc.identifier.citation | BIODRUGS, 31(3), p. 207-221 | - |
dc.identifier.issn | 1173-8804 | - |
dc.identifier.uri | http://hdl.handle.net/1942/24267 | - |
dc.description.abstract | Interleukin (IL)-1 is a pro-inflammatory cytokine that induces local and systemic inflammation aimed to eliminate microorganisms and tissue damage. However, an increasing number of clinical conditions have been identified in which IL-1 production is considered inappropriate and IL-1 is part of the disease etiology. In autoinflammatory diseases, gout, Schnitzler's syndrome, and adult-onset Still's disease, high levels of inappropriate IL-1 production have been shown to be a key process in the etiology of the disease. In these conditions, blocking IL-1 has proven very effective in clinical studies. In other diseases, IL-1 has shown to be present in disease process but is not the central driving force of inflammation. In these conditions, including type 1 and 2 diabetes mellitus, acute coronary syndrome, amyotrophic lateral sclerosis, and several neoplastic diseases, the benefits of IL-1 blockade are minimal or absent. | - |
dc.description.sponsorship | The authors did not receive funding for this review. | - |
dc.language.iso | en | - |
dc.publisher | ADIS INT LTD | - |
dc.rights | (c) Springer International Publishing Switzerland 2017 | - |
dc.title | Interleukin-1 Blockade: An Update on Emerging Indications | - |
dc.type | Journal Contribution | - |
dc.identifier.epage | 221 | - |
dc.identifier.issue | 3 | - |
dc.identifier.spage | 207 | - |
dc.identifier.volume | 31 | - |
local.format.pages | 15 | - |
local.bibliographicCitation.jcat | A1 | - |
dc.description.notes | [Mistry, Anoop] St James Univ Hosp, Dept Clin Immunol & Allergy, Wellcome Trust Brenner Bldg,Beckett St, Leeds, W Yorkshire, England. [Savic, Sinisa] St James Univ Hosp, NIH Res Leeds Musculoskeletal Biomed Res Unit NIH, Wellcome Trust Brenner Bldg,Beckett St, Leeds, W Yorkshire, England. [Savic, Sinisa] St James Univ Hosp, Leeds Inst Rheumat & Musculoskeletal Med LIRMM, Wellcome Trust Brenner Bldg,Beckett St, Leeds, W Yorkshire, England. [van der Hilst, Jeroen C. H.] Jessa Hosp, Dept Infect Dis & Immun, Stadsomvaat 11, B-3500 Hasselt, Belgium. [van der Hilst, Jeroen C. H.] Univ Hasselt, Biomed Res Inst, Hasselt, Belgium. | - |
local.publisher.place | NORTHCOTE | - |
local.type.refereed | Refereed | - |
local.type.specified | Review | - |
dc.identifier.doi | 10.1007/s40259-017-0224-7 | - |
dc.identifier.isi | 000402070900006 | - |
item.contributor | Mistry, Anoop | - |
item.contributor | Savic, Sinisa | - |
item.contributor | VAN DER HILST, Jeroen | - |
item.validation | ecoom 2018 | - |
item.fullcitation | Mistry, Anoop; Savic, Sinisa & VAN DER HILST, Jeroen (2017) Interleukin-1 Blockade: An Update on Emerging Indications. In: BIODRUGS, 31(3), p. 207-221. | - |
item.accessRights | Restricted Access | - |
item.fulltext | With Fulltext | - |
crisitem.journal.issn | 1173-8804 | - |
crisitem.journal.eissn | 1179-190X | - |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
mistry2017.pdf Restricted Access | Published version | 578.34 kB | Adobe PDF | View/Open Request a copy |
SCOPUSTM
Citations
10
checked on Sep 3, 2020
WEB OF SCIENCETM
Citations
15
checked on Apr 22, 2024
Page view(s)
56
checked on Sep 7, 2022
Download(s)
50
checked on Sep 7, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.